Abstract:There is a compelling need to find effective treatments for metastatic prostate cancer. The ideal treatment would only target metastatic lesion while sparing normal tissue. Down-regulation of specific pathways using small interfering RNA (siRNA) provides unique opportunities to target cancer cells selectively while sparing normal tissue. Prostate-specific membrane antigen (PSMA) is a type II integral membrane protein that has abundant expression on the surface of prostate carcinomas, particularly in androgen-independent, advanced and metastatic disease [1-2]. We are developing prostate specific membrane antigen (PSMA) targeted nanoplexes carrying multimodality imaging reporters together with small interfering RNA (siRNA) and a prodrug enzyme, bacterial cytosine deaminase (bCD), for theranostic imaging of metastatic prostate cancer. We have incorporated a low molecular weight PSMA binding agent in the nanoplex to target the nanoplex to prostate cancer cells [3]. Since choline kinase (Chk) is significantly upregulated in aggressive cancer cells we have used siRNA against Chk in the nanoplex. Our prototype nanoplexes are synthesized by conjugating: (i) a low molecular weight urea-based PSMA targeting moiety (2-(3-[1-carboxy-5-[7-(2,5-dioxo-pyrrolidin-1-yloxycarbonyl)-heptanoylamino]-pentyl]-ureido)-pentanedioic acid, (ii) the prodrug-activating enzyme bCD that converts nontoxic 5-fluorocytosine (5-FC) to cytotoxic 5-fluorouracil (5-FU), (iii) the multimodal imaging reporter carrier poly-L-lysine (PLL) that carries [111In]DOTA for SPECT or [Gd3+]DOTA for MR, and a near-infrared fluorescent probe Cy5.5 for optical imaging, and (iv) the siRNA delivery vector: PEI (polyethyleneimine)-PEG (polythethyeneglycol) co-grafted-polymer. Imaging studies with PSMA targeted nanoplexes were performed with PC-3 human prostate cancer xenografts genetically engineered to overexpress PSMA (PC-3 PIP) in SCID mice. Non PSMA expressing PC-3 xenografts (PC-3 FLU) were used as controls. The addition of a low molecular weight PSMA targeting moiety allowed specific targeting of the nanoplex to PSMA expressing prostate cancer cells in vivo, which was further established with blocking studies. Initial studies established the ability of the nanoplex to effectively downregulate Chk and total choline and convert the nontoxic prodrug 5-FC to 5-FU. The strategies developed here can be extended, in the future, to down-regulate multi-drug resistance pathways, or repair enzymes to increase the efficiency of chemo- or radiation therapy. 1. Schulke, N., et al., Proc Natl Acad Sci U S A, 2003; 2. Huang, X., et al., Prostate, 2004; 3. Mease, R., et al., Clin. Cancer Res., 2008. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3629. doi:10.1158/1538-7445.AM2011-3629

Structure-activity relationship study of mesyl and busyl phosphoramidate antisense oligonucleotides for unaided and PSMA-mediated uptake into prostate cancer cells

Structure-Based Design Of Tripeptide Derivatives Of α-Aminoalkylphosphonate Esters For Prostate-Specific Antigen Inhibition

Synthesis and Modeling of Novel Α-Aminoalkylphosphonate Ester Derivatives As Potent Inhibitors of Prostate-Specific Antigen; A Comparison Study

Structure-Based Drug Design of Diphenyl Α-Aminoalkylphosphonates As Prostate-Specific Antigen Antagonists.

Psma-Targeted Low Molecular Weight Urea-Sirna Conjugates For Targeted Knockdown Of Dna-Pk And Radiosensitization Of Prostate Cancer Cell Lines

Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index

Antisense oligonucleotides: absorption, distribution, metabolism, and excretion

Phosphorothioate modified oligonucleotide–protein interactions

Structural Optimization and Additional Targets Identification of Antisense Oligonucleotide G3139 Encapsulated in a Neutral Cytidinyl-Lipid Combined with a Cationic Lipid in Vitro and in Vivo

Second-generation Aptamer-Conjugated PSMA-targeted Delivery System for Prostate Cancer Therapy

A Study Modeling Bridged Nucleic Acid-Based ASOs and Their Impact on the Structure and Stability of ASO/RNA Duplexes

Abstract 3629: Theranostic Imaging of Metastatic Prostate Cancer

Synthesis and evaluation of antisense oligonucleotides prodrug with G-quadruplex assembly and lysosome escape capabilities for oncotherapy

PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery

Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system

High-Resolution Visualisation of Antisense Oligonucleotide Release from Polymers in Cells

Cytoplasmic and Nuclear Accumulation of Antisense Oligomers Incubated As Streptavidin Delivery Nanoparticles

Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo

Allele-Selective Thiomorpholino Antisense Oligonucleotides as a Therapeutic Approach for Fused-in-Sarcoma Amyotrophic Lateral Sclerosis

Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture.